Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (5)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Tedizolid phosphate (Sivextro), oral tablets or IV injection
Renal measure
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 34, posted Mar 16, 2026
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Renal guidance: Prescribing information, renal precautions and clinical pharmacology
Renal impairment, including hemodialysis, does not require a dose change for tedizolid phosphate. Select the regimen for the labeled indication and patient age. The renal statement does not extend approved treatment duration.
Source revision: DailyMed SPL version 34, posted Mar 16, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Renal Drug Handbook, 5th edition - Tedizolid phosphate
Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.
Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR. Retrieved: 2026-09-05
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Sivextro - product and source limitations
Select the regimen for the labeled indication and patient age. The renal statement does not extend approved treatment duration.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
SIVEXTRO - adult ABSSSI dosing
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Method: No renal-function dose bands specified for this summary.
Renal Drug Handbook, 5th edition - Tedizolid phosphate
Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.
Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Adult Tedizolid phosphate (Sivextro). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.
SCOPE-tedizolid · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method: No renal-function dose bands specified for this summary. Source date: DailyMed updated 2026-02-27. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Adult acute bacterial skin/skin-structure infection: 200 mg orally or IV once daily for 6 days. Give IV doses over 1 hour. IV-to-oral conversion does not change the dose. No renal adjustment is required, including during hemodialysis; dialysis does not meaningfully remove tedizolid.
Longer treatment is not the labeled course. Consider hematologic monitoring for prolonged off-label therapy. This adult card does not reproduce the label's separate pediatric weight-based schedules.
DailyMed / product prescribing information · Tedizolid phosphate (Sivextro), oral tablets or IV injection
Renal method: Renal impairment categories as defined by the cited product label Source date: DailyMed SPL version 34, posted Mar 16, 2026 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Renal guidance: Prescribing information, renal precautions and clinical pharmacology
Renal impairment, including hemodialysis, does not require a dose change for tedizolid phosphate. Select the regimen for the labeled indication and patient age. The renal statement does not extend approved treatment duration.
GlobalRPh RX List / product-label mirror · Tedizolid phosphate (Sivextro), oral tablets or IV injection
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.
Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR. Source date: 5th edition; 2019 copyright; historical reference Retrieved: 2026-09-05
Historical handbook cross-check; not a current U.S. protocol
Historical renal / replacement-therapy guidance
The 20-50, 10-20 and <10 mL/min bands retain the usual indication-specific dose. The listed regimen is 200 mg once daily for 6 days. PD removal is described as absent and HD removal below 10%; usual dosing is retained. High-flux/continuous removal is unknown, although the book retains usual dosing. These are historical RRT statements, not contemporary measured clearance for every circuit.
HB30-tedizolid-1 · Source locator: Printed page 964: renal impairment, RRT and other information
Source-specific limits
Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 964; uploaded PDF p. 983
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: Qualitative no-adjustment guidance. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
The adult institutional regimen is 200 mg IV or orally once daily. No reduction is recommended solely for renal dysfunction or hemodialysis. Duration and indication must be selected separately; this renal summary does not extend the approved treatment course.
Additional summaries stored on this page: 2 official-label, 1 RX List, 1 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
